On March 12, 2026, investors weighed profit-taking against a high-stakes pivot toward branded obesity drugs and telehealth growth.

Hims & Hers Health (NYSE:HIMS) looked like a fallen growth star earlier this year. The telehealth platform was hammered by the FDA’s aggressive crackdown on compounded GLP-1 drugs, complete with ...

The hire comes as the San Francisco company expands globally, including its recent purchase of an Australian telehealth firm ...

Hims & Hers Health (HIMS) is rated a Speculative Buy after its renewed partnership with Novo Nordisk, providing legitimate ...

Hims & Hers Health Inc HIMS shares are climbing in Thursday's premarket session. This follows a double-digit gain during ...

Consumers are paying in cash in a hotly competitive marketplace, creating a rare phenomenon for a relatively new class of prescription drugs: falling prices.

Check out the companies making headlines before the bell. Bumble — Bumble shares popped about 21% after the dating app ...

Yahoo Finance anchor Josh Lipton tracks Wednesday's top moving stocks and biggest market stories in this Market Minute. Hims ...

Hims & Hers extended its winning streak to a third consecutive day on Wednesday, jumping 10.27 percent to close at $25.88 apiece, as investors resumed buying positions after a series of analyst ...

Hims & Hers Health has hired Eli Lilly and Company’s former head of communications Kathryn Beiser to be its chief communications officer. Beiser started in the role last month, according to her ...

Hims & Hers Health, Inc.'s revenue is projected to reach $2.7B in 2026 & $3.2B in 2027, implying less than 2x forward sales. Read more on HIMS stock here.